Emerging Opportunities in the 3D Printed Drugs Market: Riding the Wave of Emergency Care Demand (Updated PDF 2023)

Aprecia Pharmaceuticals Companys SPRITAM levetiracetam is the first 3D printed drug, which has been approved by the U.S. Food and Drug Administration (FDA)

3d printed Drugs Market 2023

PORTLAND, OREGON, UNITED STATES, April 6, 2023 /EINPresswire.com/ -- Rise in the number of individuals suffering from different chronic conditions, increase in geriatric population, and surge in the number of traumatic accidents drive the global ambulance services market. Based on region, North America held the largest share in 2021, contributing to nearly two-fifths of the global ambulance service market share.

Allied Market Research has published a study report with the title 3D Printing Drugs Market Size was Valued at USD 278 Million in 2020 and is Projected to Garner USD 522 million by 2030 registering a CAGR of 6.5% from 2020 to 2030. The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and evolving market trends. The market study is a helpful source of information for the frontrunners, new entrants, investors, and shareholders in crafting strategies for the future and heightening their position in the market.

□□□□ □□ □□□ □□□□□□ □□ □□ □□□□□□□□ □□□□□ □□ □□□□□□□□□□?

The future of 3D printing drugs in pharmacies is promising, with the potential to revolutionize the way medications are manufactured and delivered to patients. Here are some potential developments and benefits:

□□□□□□□□□□□□□□□□: 3D printing can be used to create customized dosage forms that are tailored to individual patient needs. This could lead to better treatment outcomes and reduced

side effects.
□□□-□□□□□□□ □□□□□□□□□□□□□□□: 3D printing allows for the rapid production of small batches of drugs, which could improve supply chain efficiency and reduce waste.
□□□□□□□ □□□□□ □□□□□□□□□ □□□□□□□□: 3D printing enables the creation of complex drug delivery systems, such as implants and microneedles, which can improve drug efficacy and patient compliance.
□□□□□□□□□□ □□□□□□□□□□□□□□: 3D printing can be used to create drug formulations with improved solubility, bioavailability, and stability, which can enhance drug efficacy and reduce the need for preservatives and other additives.
□□□□□□ □□□□□□□□: By enabling more efficient drug manufacturing and reducing waste, 3D printing has the potential to lower the cost of medications.

□□□□ □□□□□□□ □□□□ □□□□□□□ □□□□□ □□□□□□□ □□□□ □□□□□□□□ □□□□□:
https://www.alliedmarketresearch.com/request-sample/4508

□□□□□□□ □□□□□□□□□□:

3D printing drugs, also known as pharmaceutical 3D printing or 3D printed medicine, refers to the use of 3D printing technology to create personalized and precise dosage forms for drugs. This technology allows for the creation of complex structures that can be customized to fit the specific needs of individual patients, such as their age, weight, medical condition, and other factors that can affect drug absorption and efficacy. The process involves designing and printing drug formulations layer by layer, using materials such as polymers, gels, and powders. These materials can be loaded with the active pharmaceutical ingredient (API), as well as other excipients that improve drug solubility, stability, and release. The resulting dosage forms can have different shapes, sizes, and textures, such as tablets, capsules, and implants, and can be tailored to meet the specific requirements of different drug delivery routes, such as oral, topical, and implantable.

□□-□□□□□□□□ □□□□□□ □□□□□□□□□□

□Aprecia Pharmaceuticals - Aprecia was the first company to gain FDA approval for a 3D-printed drug, Spritam, which is used to treat epilepsy.
□FabRx - FabRx is a UK-based company that specializes in 3D printing of personalized medicines, including drug-loaded filaments, pellets, and tablets.
□GlaxoSmithKline - GSK has been developing 3D-printed medicines using its proprietary "Inkjet" technology, which allows for the printing of drugs with precise dosages and formulations.
□Merck & Co. - Merck has been exploring the use of 3D printing in drug development, including the production of personalized dosages and drug delivery systems.
□Sanofi - Sanofi has partnered with the 3D printing company Aprecia to develop new formulations of medications using 3D printing technology.

□□ □□□□□□□□ □□□□□□ □□□□□□□ □□□□□□□□□□□□□□

The 3D printed drugs market can be segmented in various ways based on different criteria, including:

By Technology: The market can be segmented based on the different 3D printing technologies used to produce drugs, such as powder bed fusion, binder jetting, and fused filament fabrication.
By Application: The market can be segmented based on the different therapeutic areas in which 3D-printed drugs can be used, such as neurology, oncology, cardiology, and others.
By End-user: The market can be segmented based on the different end-users of 3D-printed drugs, such as hospitals, research institutes, and pharmaceutical companies.
By Type: The market can also be segmented based on the type of 3D-printed drugs, such as oral tablets, capsules, implants, and others.

Europe is estimated to account for four-sevenths share in 2020, and is expected to dominate the market throughout the forecast period, due to presence of well-established healthcare systems and increase in prevalence of dysphagia. In addition, increase in adoption of 3D printed drugs is anticipated to provide new growth opportunities for the key players in the European market. However, Asia-Pacific is projected to grow at the highest growth rate during the analysis period, owing to increase in healthcare expenditure, rise in awareness related to 3D printing technique, presence of large patient pool, and developments in healthcare infrastructure.

□□□□□□□□ □□□ □□□□□□: https://www.alliedmarketresearch.com/purchase-enquiry/4508

By Region Outlook

• North America
(U.S., Canada, Mexico)
• Europe
(Germany, France, UK, Italy, Spain, Rest of Europe)
• Asia-Pacific
(Japan, China, India, Rest of Asia-Pacific)
• LAMEA
(Brazil, Saudi Arabia, South Africa, Rest of LAMEA)

Contact Details:

David Correa
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
help@alliedmarketresearch.com

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

David Correa
Allied Analytics LLP
+ +1-800-792-5285
email us here